Drug Shortage Report for ACTEMRA
| Report ID | 142457 |
| Drug Identification Number | 02424770 |
| Brand name | ACTEMRA |
| Common or Proper name | ACTEMRA |
| Company Name | HOFFMANN-LA ROCHE LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | TOCILIZUMAB |
| Strength(s) | 162MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | pre-filled syringe |
| ATC code | L04AC |
| ATC description | IMMUNOSUPPRESSANTS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2021-11-20 |
| Actual start date | |
| Estimated end date | 2021-12-31 |
| Actual end date | 2021-11-25 |
| Shortage status | Resolved |
| Updated date | 2021-11-26 |
| Company comments | During the COVID-19 pandemic, the demand for Actemra has been increasing at a global level. Roche has started to apply mitigation strategies to support our efforts to increase the supply of Actemra. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 7070 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 5M8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2021-11-26 | English | Compare |
| v7 | 2021-11-25 | French | Compare |
| v6 | 2021-11-25 | English | Compare |
| v5 | 2021-11-21 | English | Compare |
| v4 | 2021-09-08 | French | Compare |
| v3 | 2021-09-08 | English | Compare |
| v2 | 2021-07-13 | French | Compare |
| v1 | 2021-07-13 | English | Compare |
Showing 1 to 8 of 8